Acalabrutinib, umbralisib and ublituximab regimen (AU2) demonstrates high response rate and undetectable molecular minimal residual disease (MRD) in patients (pts) with de novo mantle cell lymphoma (MCL)
BACKGROUNDWe present an update of a phase 2 study of AU2 in pts with previously untreated MCL (NCT04783415).
Authors
- Hari P. Miskin
- Geoffrey Shouse (ORCID: https://orcid.org/0000-0002-7917-5713)
- Tycel Phillips (ORCID: https://orcid.org/0000-0003-2143-9672)
- Alexandra Muir (ORCID: https://orcid.org/0000-0003-3346-8892)
- Alexey Valeryevich Danilov (ORCID: https://orcid.org/0000-0003-4461-0970)
- Peter Sportelli
- Paolo Lopedote (ORCID: https://orcid.org/0000-0002-7764-4336)
- Lu Chen (ORCID: https://orcid.org/0000-0001-9708-341X)
- Carly Rolender
Institutions
- City Of Hope National Medical Center (US)
- CDG Therapeutics (United States) (US)
Publication Details
- Journal
- International Journal of Cancer Care and Delivery
- Published
- 2024-10-11
- DOI
- https://doi.org/10.53876/001c.124491
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00